stockportfolio.pro
Inhibrx Biosciences, Inc. (INBX)
Healthcare · Biotechnology · NasdaqGS
Inhibrx Biosciences, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.30M | $1.80M | $200,000 | $1.30M |
| Gross profit | — | — | — | — |
| Net income | $-115.33M | $-241.36M | $1.69B | $-140.06M |
| Net margin | -8864.3% | -13408.9% | 843786.0% | -10773.5% |
Source: Inhibrx Biosciences, Inc. SEC filings (10-K).
Explore 4 years of Inhibrx Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track INBX in your portfolio →
Inhibrx Biosciences, Inc. financial history by metric
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc. — frequently asked questions
What is Inhibrx Biosciences, Inc.'s revenue?
Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.30M for fiscal year 2025, up 550.0% from the prior year, according to its SEC filings.
Is Inhibrx Biosciences, Inc. profitable?
No — INBX reported a net loss of $-140.06M in fiscal 2025.
What is INBX's P/E ratio?
Inhibrx Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Inhibrx Biosciences, Inc. growing?
INBX's revenue grew at roughly -0.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Inhibrx Biosciences, Inc. have?
As of fiscal year 2025, INBX carried roughly $100.56M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Inhibrx Biosciences, Inc.'s market cap?
Inhibrx Biosciences, Inc. (INBX) has a market capitalization of about $1.32B, based on the latest data in our nightly-refreshed cache.
When does Inhibrx Biosciences, Inc.'s fiscal year end?
INBX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Inhibrx Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.